David Hass, MD
Gastroenterology · Hamden, CTNPI 1225177769
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $142,980 of the $172,749 with a category attached, or 82.8%. 28 manufacturers reported payments, led by Medtronic at 54.5% of the total. Reporting peaked in 2021 at $53,984 and has fallen 86.2% since, to $7,429 in 2025. Among gastroenterology clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 277 payments — averaging $623.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$94K
- Covidien LP$74K
- AbbVie$1K
- Iterative Scopes, Inc.$1K
- Takeda Pharmaceuticals U.S.A., Inc.$445
- Ferring Pharmaceuticals Inc.$196
- plus $2K from 22 others
Across 4 payments — averaging $4321.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Covidien LP$13K
- Braintree Laboratories, Inc.$5K
What the payments were for
- Consulting fees$23,73814%
- Speaking & faculty fees$142,98083%
- Travel & lodging$1,5791%
- Food & beverage$4,4213%
- Education$300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 40 | $94,151 |
| Covidien LP | 43 | $73,584 |
| AbbVie(2 entities) | 84 | $1,368 |
| Iterative Scopes, Inc. | 1 | $1,238 |
| Takeda Pharmaceuticals U.S.A., Inc. | 29 | $445 |
| Ferring Pharmaceuticals Inc. | 10 | $196 |
| Johnson & Johnson | 9 | $190 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $169 |
| Ardelyx, Inc. | 7 | $147 |
| QOL Medical, LLC | 4 | $126 |
| Vericel Corporation | 1 | $125 |
| Pfizer | 6 | $119 |
| Bristol Myers Squibb | 4 | $113 |
| Gilead | 6 | $101 |
| Boston Scientific | 1 | $99 |
| Conmed Corporation | 1 | $98 |
| Intercept Pharmaceuticals, Inc. | 5 | $91 |
| Ironwood Pharmaceuticals, Inc | 3 | $63 |
| Regeneron Healthcare Solutions, Inc. | 2 | $55 |
| Lilly USA, LLC | 2 | $48 |
| Sanofi | 2 | $46 |
| Pentax Of America, Inc. | 2 | $36 |
| Madrigal Pharmaceuticals | 1 | $35 |
| Exact Sciences | 1 | $28 |
| Braintree Laboratories, Inc. | 1 | $25 |
| Portola Pharmaceuticals, LLC | 1 | $24 |
| Vivus LLC | 1 | $18 |
| Shionogi Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$172,749 in reported general payments places this provider in the 95th percentile of 326 gastroenterology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 49 | $133,666 |
| ThalomidThalidomide | 14 | $73,677 |
| Dexlansoprazole DrDexlansoprazole | 95 | $35,882 |
| LinzessLinaclotide | 29 | $23,472 |
| MotegrityPrucalopride Succinate | 27 | $15,847 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 191 | $12,019 |
| DexilantDexlansoprazole | 13 | $7,794 |
| Mesalamine | 22 | $6,116 |
| Omeprazole | 181 | $3,375 |
| Pantoprazole Sodium | 182 | $2,528 |
| Sucralfate | 12 | $1,791 |
| Famotidine | 151 | $1,666 |
| Esomeprazole Magnesium | 49 | $1,478 |
| Cholestyramine LightCholestyramine | 13 | $1,109 |
| Rabeprazole Sodium | 18 | $1,031 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $1,368 | $157,13878 claims |
| Bristol Myers SquibbThalomid | $113 | $73,67714 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity, Dexilant | $445 | $23,64140 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 326 gastroenterology providers in Connecticut.
Other gastroenterology in Hamden
- Paul FeuerstadtHamden$1M
- Renuka UmashankerHamden$197K
- Karl LangbergHamden$17K
- Dean ChangHamden$16K
- Benigno VarelaHamden$16K
- Mark TaylorHamden$13K
- James FrestonFarmington$772K
- Loren LaineWest Haven$451K
- Martin HoffmanHartford$317K
- Colin SwalesHartford$285K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.